Plus   Neg

International Flavors & Fragrances Revises Outlook - Quick Facts

International Flavors & Fragrances Inc. (IFF) announced the company now expects fiscal 2019 adjusted EPS excluding amortization to be $6.15 to $6.35 revised from previous outlook range of $6.30 - $6.50, principally due to a change in the average effective tax rate associated with the amortization of intangible assets and changes in redeemable non-controlling interests. On a combined basis, and excluding the impact of currency, adjusted EPS excluding amortization is expected to be 6 to 9%. The company expects adjusted EPS to be $4.85 to $5.05 revised from the prior guidance range of $4.90 to $5.10.

For the full year, the company now expects sales in a range of $5.15 and $5.25 billion, updated from previous guidance range of $5.2 billion - $5.3 billion. On a combined basis and excluding the impact of currency, growth is expected to be 3 to 5%.

For the second-quarter, adjusted EPS excluding amortization was $1.61 per share compared to $1.71 prior year, as adjusted operating profit growth was more than offset by higher interest expense and shares outstanding.

Second-quarter reported net sales totaled $1.3 billion, an increase of 40% from $920 million, prior year, including the contribution of sales related to Frutarom. On a combined basis, currency neutral sales increased 1%, for the quarter.

The Board authorized a 3%, or $0.02 increase, in the quarterly dividend to $0.75 per share. The quarterly dividend is payable on October 4, 2019 to shareholders of record as of September 23, 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple is tracking iPhones that were stolen from its retail stores in recent days during the civil unrest, according to reports citing a warning message popping up on the stolen iPhones. Four current and former senior executives from two major broiler chicken producers, including Pilgrim's Pride CEO Jayson Penn, have been indicted for price fixing. Kezar Life Sciences, Inc. (KZR) - Shares of the clinical-stage biotechnology company soared nearly 80% after closing bell. The company's lead drug candidate is KZR-616, a selective inhibitor of immunoproteasome that plays a crucial role in the immune system. KZR-616 is under a phase Ib/II study in...
Follow RTT